{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:22:51Z","timestamp":1789384971370,"version":"build-2803163510"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T00:00:00Z","timestamp":1359072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0055111","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T22:17:13Z","timestamp":1359152233000},"page":"e55111","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness of Efavirenz-Based Regimens in Young HIV-Infected Children Treated for Tuberculosis: A Treatment Option for Resource-Limited Settings"],"prefix":"10.1371","volume":"8","author":[{"given":"Janneke H.","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine G.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Hamangaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bositis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,25]]},"reference":[{"key":"ref1","unstructured":"UNAIDS (2012) Together We Will End AIDS. Geneva, Switzerland: Joint United Nations Programme on HIV\/AIDS."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0163-4453(03)00121-X","article-title":"Global epidemiology of paediatric tuberculosis","volume":"48","author":"T Walls","year":"2004","journal-title":"J Infect"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00002030-199810000-00011","article-title":"Persistent and chronic lung disease in HIV-1 infected and uninfected African children","volume":"12","author":"PM Jeena","year":"1998","journal-title":"AIDS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(02)11082-8","article-title":"Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study","volume":"360","author":"C Chintu","year":"2002","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1164\/ajrccm.151.1.7812542","article-title":"Accelerated course of human immunodeficiency virus infection after tuberculosis","volume":"151","author":"C Whalen","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"ref6","unstructured":"WHO (2010) Antiretroviral therapy for HIV infection in infants and children: Towards universal access, Recommendations for a public health approach, 2010 revision. Geneva, Switzerland: World Health Organization."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/QAD.0b013e328339e576","article-title":"Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment","volume":"24","author":"M Yotebieng","year":"2010","journal-title":"AIDS"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3851\/IMP1455","article-title":"Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries","volume":"14","author":"G Maartens","year":"2009","journal-title":"Antivir Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/jop.2005.21.166","article-title":"Corneal endothelial deposits associated with rifabutin use","volume":"21","author":"AB Coutinho","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref10","unstructured":"Bobat R, Kiepiela P, Kindra G, Reddy S, Esterhuizen T, <etal>et al<\/etal>. (2008) Resistance in ART-naive paediatric subjects with chronic HIV-1 infection: experiences from a pilot study. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22\u201325 July 2007; Sydney, Australia."},{"key":"ref11","unstructured":"The HIV-CAUSAL Collaboration (2012) The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/INF.0b013e318125720a","article-title":"Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand","volume":"26","author":"T Puthanakit","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa1113249","article-title":"Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children","volume":"366","author":"A Violari","year":"2012","journal-title":"N Engl J Med"},{"key":"ref14","unstructured":"WHO (2006) Antiretroviral therapy of HIV infection in infants and children: Towards universal access. Recommendations for a public health approach. Geneva, Switzerland: World Health Organization."},{"key":"ref15","unstructured":"WHO (2008) Report of the WHO Technical Reference Group, Paediatric HIV\/ART Care Guideline Group Meeting. Geneva, Switzerland: World Health Organization."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/QAI.0b013e31805c9d52","article-title":"High prevalence of subtherapeutic plasma concentrations of efavirenz in children","volume":"45","author":"Y Ren","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jac\/dkn112","article-title":"Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children","volume":"61","author":"U Wintergerst","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/QAI.0b013e318235e560","article-title":"Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda","volume":"58","author":"Q Fillekes","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.01594-08","article-title":"Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children","volume":"53","author":"D Hirt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1542\/peds.2006-0925","article-title":"Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021","volume":"120","author":"RE McKinney Jr","year":"2007","journal-title":"Pediatrics"},{"key":"ref21","unstructured":"Capparelli E, Rochon-Duck M, Robbins B, Rathore M, Britto P, et al. Age-related pharmacokinetics of efavirenz solution. 16th Conference on Retroviruses and Opportunistic Infections, 8\u201311 February 2009; Montreal, Canada."},{"key":"ref22","unstructured":"Bolton C, Samson P, Capparelli E, Bwakura-Dangarembizi M, Jean-Phillipe P, <etal>et al<\/etal>. (2012) Strong influence of CYP2B6 genotypic polymorphisms on efavirenz pharmacokinetics in HIV-infected children &lt;3 years of age and implications for dosing. Conference on Retroviruses and Opportunistic Infections, 2012 5\u20138 March Seattle, WA."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e19006","DOI":"10.1371\/journal.pone.0019006","article-title":"HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy","volume":"6","author":"JH van Dijk","year":"2011","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1471-2334-9-169","article-title":"Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis","volume":"9","author":"JH van Dijk","year":"2009","journal-title":"BMC Infect Dis"},{"key":"ref25","unstructured":"WHO (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach \u20132010 version. Geneva, Switzerland: World Health Organization."},{"key":"ref26","first-page":"377","article-title":"Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines","volume":"11","author":"N von Hentig","year":"2006","journal-title":"Eur J Med Res"},{"key":"ref27","unstructured":"WHO The WHO child growth standards. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/childgrowth\/en\/index.html\" xlink:type=\"simple\">http:\/\/www.who.int\/childgrowth\/en\/index.html<\/ext-link>. Accessed August 1, 2005."},{"key":"ref28","unstructured":"WHO (2001) Iron deficiency anaemia: assessment, prevention and control. A guide for program managers. Geneva, Switzerland: World Health Organization."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/505210","article-title":"Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin","volume":"43","author":"W Manosuthi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/dkm484","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis","volume":"61","author":"K Cohen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","article-title":"Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration","volume":"42","author":"G Ramachandran","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref32","unstructured":"Oudijk JM, McIlleron HM, Mulenga V, Chintu C, Merry C, <etal>et al<\/etal>. (2009) Pharmacokinetics of nevirapine in young children during combined ART and rifampicin-containing antituberculosis treatment. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19\u201322 July 2009; Cape Town, South Africa."},{"key":"ref33","unstructured":"Barlow-Mosha L, Musoke P, Parsons T, Ajuna P, Lutajjumwa M, <etal>et al<\/etal>. (2009) Nevirapine concentrations in HIV-infected Ugandan children on adult fixed-dose combination tablet ART, with and without rifampicin-based treatment for active M. tuberculosis infection. 16th Conference on Retroviruses and Opportunistic Infections, 8\u201311 February 2009; Montreal, Canada."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350801300414","article-title":"Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin","volume":"13","author":"A Avihingsanon","year":"2008","journal-title":"Antivir Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"A Boulle","year":"2008","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","article-title":"Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial","volume":"53","author":"S Swaminathan","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/QAD.0b013e328310407e","article-title":"Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults","volume":"22","author":"JB Nachega","year":"2008","journal-title":"AIDS"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"RM Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.285.9.1155","article-title":"Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial","volume":"285","author":"S Staszewski","year":"2001","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1185\/030079904125004006","article-title":"Triple nucleoside treatment with abacavir plus the lamivudine\/zidovudine combination tablet (COM) compared to indinavir\/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014)","volume":"20","author":"A Vibhagool","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"CJ la Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3851\/IMP1757","article-title":"Lopinavir exposure is insufficient in children given double doses of lopinavir\/ritonavir during rifampicin-based treatment for tuberculosis","volume":"16","author":"H McIlleron","year":"2011","journal-title":"Antivir Ther"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e3181642257","article-title":"Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis","volume":"47","author":"Y Ren","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","article-title":"Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group","volume":"351","author":"DW Cameron","year":"1998","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/INF.0b013e31822539f6","article-title":"Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa","volume":"30","author":"TM Meyers","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJM199912163412502","article-title":"Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team","volume":"341","author":"SE Starr","year":"1999","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1542\/peds.2006-1367","article-title":"Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen","volume":"119","author":"HJ Scherpbier","year":"2007","journal-title":"Pediatrics"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00002030-200101260-00014","article-title":"Tolerance of efavirenz in children","volume":"15","author":"JP Teglas","year":"2001","journal-title":"AIDS"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ijid.2007.10.008","article-title":"Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children","volume":"12","author":"K Lapphra","year":"2008","journal-title":"Int J Infect Dis"},{"key":"ref50","unstructured":"FDA (2012) Sustiva Prescribing Information. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm\" xlink:type=\"simple\">www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm<\/ext-link>. Accessed August 20, 2012."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/INF.0b013e318223b680","article-title":"Absence seizures associated with efavirenz initiation","volume":"30","author":"R Strehlau","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","article-title":"High prevalence of the CYP2B6 516G\u2013&gt;T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe","volume":"64","author":"C Nyakutira","year":"2008","journal-title":"Eur J Clin Pharmacol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0055111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T23:54:43Z","timestamp":1687996483000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0055111"}},"subtitle":[],"editor":[{"given":"Andrew","family":"Boulle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0055111","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,25]]}}}